In the United States, the most common of the aggressive non-Hodgkin lymphomas (NHLs) is diffuse large B-cell lymphoma (DLBCL), which accounts for between 22% and 24% of newly diagnosed B-cell NHL cases.1 Although DLBCL can affect children and young adults, it is most commonly diagnosed in individuals between the ages of 65 and 74 years, with a median age at diagnosis of 66 years.2,3 Given the aggressive nature of DLBCL, patients often present with lymphadenopathy, extranodal involvement, and other constitutional symptoms thatrequire immediate treatment.1
The treatment spectrum for DLBCL has expanded significantly in recent years, particularly for patients with relapsed or refractory (R/R) disease. Mechanisms of action differ greatly among agents, reflecting the complex pathophysiology and genetic variations of the disease. This article reviews the advances in DLBCL understanding that have led to the approval of new agents andsubsequent utilization of new mechanisms.
The current standards of care for first-line DLBCL treatment include the combination chemoimmunotherapy regimen of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP). The varying numbers of cycles and use in combination with or without radiotherapy (RT) depends upon the stage of disease at presentation.1 The addition of rituximab to CHOP was associated with a 2-year event-free survival of 57% in elderly patients in a 2002 randomized trial (LNH-98.5), which, along with results of other trials, led to the FDA approval of this combination therapy.4,5 Although durable remission can be achieved with R-CHOP in about 60% of patients, its use has resulted in poorer long-term outcomes for patients with double-hit andtriple-hit lymphomas (DHL and THL).1
In 2007, the International Harmonization Project issued guidelines on malignant lymphoma response criteria, defining relapsed disease as consisting of new lesions greater than 1.5 cm in any axis during or after the completion of therapy or a 50% or greater increase in the sum of the product of diameters of a previously involved node(s) or other lesion(s).6 The authors also defined refractory, or progressive, disease as entailing a 50% or greater increase in the size of a lymph node with a prior short-axis diameter of less than 1.0 cm to a size of 1.5 cm 1.5 cm (or a long-axis size of > 1.5 cm).6
For patients with R/R disease, high-dose chemotherapy and autologous stem cell transplant (ASCT) may offer the chance for cure, but several factors may limit the utility of this approach. For example, in the treatment of patients with MYC-positive R/R DLBCL, ASCT is considered controversial because it has produced poorer outcomes in patients with DHL.1 Additionally, patients who are older or have comorbidities may be inappropriate candidates for this approach,7 and patients with disease that is unresponsive to second-line chemotherapy may have poorer prognoses (ie, poorer rates of long-term survival) and incur added toxicity from the chemotherapy.7 Even when including patients who undergo high-dose, salvage chemotherapy and subsequent ASCT, patients with R/R DLBCL have a 1-year survival rate of 28%.1 Hence, in a search for improved outcomes in the R/R setting, clinical studies have focused on DLBCL subtypes, especially in those ineligible for transplant or who have relapsed following transplant.1
Another option for patients in the relapsed setting is chimeric antigen receptor (CAR) T-cell therapy, which entails the genetic modification of autologous T cells via cloned DNA plasmids carrying a viral recombinant vector in addition to T-cell receptor-expressing genes. CAR T-cell therapy plays an important role in the R/R DLBCL setting, with reported 2-year remissions and a complete response (CR) rate in 40% of patients and 25% DHL/THL patients.1 Other therapeutic classes that have been explored for DLBCL include phosphoinositide 3-kinase (PI3K) inhibitors, B-cell lymphoma 2 (BCL2) inhibitors, and checkpoint inhibitors.1,8-10
Given reduced survival in patients who are unresponsive to subsequent lines of therapy and the toxicity involved, a great need exists for novel agents in the R/R DLBCL setting. Recent entrants to the R/R DLBCL treatment landscape include the antibody-drug conjugate (ADC) polatuzumab vedotin-piiq, the selective inhibitor of nuclear export, selinexor, and the monoclonal antibody tafasitamab-cxix (TABLE 111-20).
Polatuzumab vedotin-piiq was approved by the FDA in 2019 and is indicated in combination with bendamustine and rituximab in adults with RR DLBCL not otherwise specified, following at least 2 previous therapies.11 It is an ADC wherein the monoclonal antibody is linked to an antimitotic agent, monomethyl auristatin E (MMAE). The ADC targets the B-cell surface protein CD79B and, after binding to the surface protein, is internalized by the cell. Lysosomal enzymes then cleave the link between the antibody and MMAE, the latter of which binds microtubules, thereby inhibiting cell division and inducing apoptosis.11
A 2020 phase 1b/2 study (NCT02257567) randomized patients with R/R DLBCL who were ineligible for ASCT to receive polatuzumab vedotin-piiq with bendamustine and rituximab (pola-BR) or bendamustine and rituximab (BR) alone.12 The phase 2 primary end point was CR; secondary end points included overall response rate (ORR) at end of treatment, superior overall response, duration of response (DOR), and progression-free survival (PFS) assessed per independent review committee (IRC).12 With a median follow-up of 22.3 months, the CR was significantly higher in the pola-BR group (40% vs 17.5% in the BR group; P = .026).12 Overall survival rate was also significantly higher in the pola-BR group (12.4 vs 4.7 months in the BR group; HR, 0.42; 95% CI, 0.24-0.75; P = .002).12 Similarly, median PFS was significantly longer at 9.5 months in the pola-BR group compared with 3.7 months in the BR group (HR, 0.36; 95% CI, 0.21-0.63; P < .001).12 Also, DOR was longer at 12.6 months in the pola-BR group vs 7.7 months in the BR group (HR, 0.47; 95% CI, 0.19-1.14).12 Finally, the pola-BR group had a 58% reduction in risk of death compared with the BR group (HR, 0.42; 95% CI, 0.24-0.75; P = .002).12 In terms of safety, grade 3/4 anemia, neutropenia, thrombocytopenia, and peripheral neuropathy occurred more frequently in the pola-BR group than in the BR group.12 Polatuzumab vedotin-piiq was deemed an effective agent that might provide a therapeutic option for patients with R/R DLBCL who were not ideal candidates for CAR T-cell therapy.12
In 2020, selinexor was approved by the FDA for use in adult patients with R/R DLBCL (including follicular lymphoma-derived DLBCL) after at least 2 lines of systemic treatment.13 Selinexor inhibits nuclear export of tumor suppressor proteins by blocking exportin 1.13
The FDA approval was based on results of the open-label single-arm phase 2 SADAL trial (NCT02227251), which included patients 18 years or older with DLBCL (based on pathologic confirmation) with an Eastern Cooperative Oncology Group (ECOG) score of 2 or less, who had 2 to 5 lines of prior therapy, and who had progressed following or were ineligible for ASCT.14 The primary end point of the SADAL trial was ORR (comprising patients with CR or PR per 2014 Lugano criteria), with secondary end points consisting of DOR and disease control rate.14 Patients received the 60-mg oral selinexor on the first and third day of each week until disease progression or unacceptable toxicity occurred.14
The updated phase 2b ORR was 28.3% with a disease control rate of 37% (95% CI, 28.6-46.0). Of 36 responders, CRs were reported in 13 evaluable patients and PRs were reported in 23 patients. At a median follow-up of 11.1 months, the median DOR was 9.3 months (95% CI, 4.8-23.0). For those with a CR, median DOR was 23.0 months (95% CI, 10.4-23.0); median DOR was 4.4 months for those with a PR (95% CI, 2.0not evaluable).14,15 To address potential differences by subtype, the SADAL trial also included a subgroup analysis of patients with the germinal center B-cell (GCB)like subtype (n = 59), which demonstrated an ORR of 33.9%, a 14% CR rate, and a 20% PR rate, whereas the patients with a non-GCB subtype (n = 63) had an ORR of 20.6%. At the time of data cutoff, 7%(n = 9) of patients showed continuing response.14,15 The SADAL trial also included 5 patients with the unclassified subtype, in 1 of whom a CR was achieved and in 2 of whom a PR was achieved.15With respect to safety, 98% of patients in the SADAL trial had at least 1 treatment-emergent adverse event (TEAE). The most frequent grade 3/4 events were thrombocytopenia, neutropenia, anemia, fatigue, hyponatremia, and nausea.14 Among serious AEs affecting 48% of patients, the most common were pyrexia, pneumonia, and sepsis.14 Gastrointestinal AEs werereported in 80% of patients, hyponatremia in 61%, and central neurologic events (which included dizziness and altered mental status) in 25%.16 Trial investigators concluded that selinexor improved survival considerably and that it presented a nonchemotherapy oral option for patients with R/R DLBCL.14
Tafasitamab-cxix is a CD19-targeting monoclonal antibody that gained FDA approval in 2020 for use with lenalidomide in adults with R/R DLBCL who are ineligible for ASCT, including patients with low-grade lymphoma derived DLBCL.17 Tafasitamab-cxix binds to the pre-B and mature B-lymphocyte surface antigen CD19, which is expressed in DLBCL and other B-cell malignancies.17 Tafasitamab-cxix, once bound to CD19, facilitates B-lymphocyte lysis via apoptosis and immune effector mechanisms that encompass antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.17
The FDA approval of tafasitamab-cxix was based on data from the phase 2, single-arm, multicenter, open-label L-MIND trial (NCT02399085).17,18 The L-MIND trial included patients 18 years or older with R/R DLBCL who had received 1 to 3 previous therapies ( 1 of which incorporated a CD20-directed regimen), had an ECOG score of 0 to 2, and were ASCT ineligible.18 Patients were administered tafasitamab-cxix and lenalidomide in 28-day cycles and continued to receive tafasitamab-cxix every 2 weeks after cycle 12 until disease progression.18 Objective response rate (ie, PR and CR) was the primary end point per IRC, which implemented PET imaging; secondary end points included investigator-assessed objective response rate, DOR, OS, PFS, biomarker analyses, and safety.18 Eighty patients were included in the full analysis set (FAS), receiving tafasitamab-cxix plus lenalidomide.18 Of the FAS, the objective response rate was 60.0% (95% CI, 48.4%-70.8%) and the CR rate was 42.5% (34/80).18 The rate of patients achieving a 12-month DOR rate was comparable across subgroups, with 70.5% of patients who received 1 prior line of therapy achieving a 12-month DOR (95% CI, 47.2%-85.0%) and 72.7% of patients who had 2 or more prior lines of therapy achieving a 12-month DOR (95% CI, 46.3%-87.6%).18
Outcomes in patients with GCB DLBCL (n = 37) were promising, with an objective response rate of 48.6%, a 12-month DOR rate of 53.5%, and a 12-month OS rate of 65.4% (based upon the Hans algorithm). Outcomes in patients with non-GCB DLBCL (n = 21) were an improvement over those with the GCB subtype, with an objective response rate of 71.4%, a 12-month DOR rate of 83.1%, and a 12-month OS rate of 84.2%.18 IRC-evaluated data from a 2-year follow up of the L-MIND trial showed an objective response rate of 58.8% (47/80) and CR rate of 41.3% (33/80).19 The 2-year follow up data also showed a median DOR of 34.6 months, with a 31.6-month median OS and a 16.2-month median PFS.19
Safety data from the preliminary L-MIND trial results showed that the most frequent TEAEs (of any grade) were neutropenia (48%), thrombocytopenia (32%), anemia (31%), diarrhea (30%), pyrexia (22%), and asthenia (20%).20 A lenalidomide dose reduction was required in 42% of patients; 72% of patients could remain on daily lenalidomide at 20 mg or higher.20 Trial investigators concluded that the combination of tafasitamab-cxix and lenalidomide was well tolerated and did not lead to compounded AEs.20
The promising data from recent trialsparticularly from their DLBCL subtype based subgroupsunderscore the importance of understanding the unique prognoses and responses that these subtypes confer on patient outcomes. The establishment of DLBCL subtypes as prognostic and therapeutic response factors has fueled a search for more specific molecular targets in the disease process. In addition, the importance of subtype characterization is evidenced by ongoing diagnostic assay development (for use in conjunction with immunohistochemistry). As exemplified by the patient populations in these trials, new therapeutic options with distinct mechanisms of actions are needed for patients with R/R DLBCL who are ineligible for ASCT. Multiple studies of targeted agents in the R/R DLBCL setting are under way that include CAR T-cell, bispecific T-cell engager, programmed death receptor 1 (PD-1) inhibitor, and BCL2 inhibitor therapies.1 Continued development of clinically applicable diagnostics holds promise for improved prognostic capability and assessment of therapeutic response. With improved diagnostics, further elucidation of DLBCL-driver mutations can continue to provide additional DLBCL subtype-specific options and, hence, more treatments tailored to individual patients.
References1. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604-616. doi:10.1002/ajh.254602. Diffuse large B-cell lymphoma. Lymphoma Research Foundation. Accessed October 12, 2020. https://lymphoma.org/aboutlymphoma/nhl/dlbcl/3. Cancer stat facts: NHL diffuse large B-cell lymphoma (DLBCL). National Cancer Institute. Accessed October 12, 2020. https://seer.cancer.gov/statfacts/html/dlbcl.html4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. doi:10.1056/NEJMoa0117955. Rituxan plus CHOP approved for diffuse large B-cell lymphoma. Cancer Network. February 28, 2006. Accessed November 6, 2020. https://www.cancernetwork.com/view/rituxan-plus-chop-approved-diffuse-large-b-cell-lymphoma6. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. doi:10.1200/JCO.2006.09.24037. Elstrom RL, Martin P, Ostrow K, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010;10(3):192-196. doi:10.3816/CLML.2010.n.0308. Oki Y, Kelly KR, Flinn I, et al. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica. 2017;102(11):1923-1930. doi:10.3324/haematol.2017.1728829. Ansell S, Gutierrez ME, Shipp MA, et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood.2016; 128(22):183. doi:10.1182/blood.V128.22.183.18310. Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698-2704. doi:10.1200/JCO.2015.65.978911. POLIVY. Prescribing information. Genentech, Inc; 2020. Accessed October 22, 2020. https://www.gene.com/download/pdf/polivy_prescribing.pdf12. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155-165. doi:10.1200/JCO.19.0017213. XPOVIO. Prescribing information. Karyopharm Therapeutics, Inc; 2020. Accessed October 22, 2020. https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf14. Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511-e522. doi:10.1016/S2352-3026(20)30120-415. Karyopharm reports updated data from the phase 2b SADAL study at the 2019 International Conference on Malignant Lymphoma. News release. Karyopharm. June 19, 2019.Accessed June 28, 2020. https://www.globenewswire.com/news-release/2019/ 06/19/1871363/0/en/Karyopharm-Reports-Updated-Data-from-the-Phase-2b-SADAL-Study-at-the-2019-International-Conference-on-Malignant-Lymphoma.html16. FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma. News release. FDA. June 22, 2020. Accessed June 28, 2020. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma17. Monjuvi. Prescribing information. MorphoSys US Inc; 2020. Accessed October 22, 2020. https://www.monjuvi.com/pi/monjuvi-pi.pdf18. Duell J, Maddocks KJ, Gonzalez-Barca E, et al. Subgroup analyses from L-Mind, a phase II study of tafasitamab (MOR208) combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2019;134(suppl 1):1582. doi:10.1182/blood-2019-12257319. MorphoSys and Incyte announce long-term follow-up results from L-MIND study of tafasitamab in patients with r/r DLBCL. News release. Morpho-Sys. May 14, 2020. Accessed June 26, 2020. https://www.morphosys.com/media-investors/media-center/morphosys-and-incyte-announce-long-term-follow-up-results-from-l-mind20. Salles GA, Duell J, Gonzlez-Barca E, et al. Single-arm phase II study of MOR208 combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: L-Mind. Blood. 2018;132(suppl 1):227. doi:10.1182/blood-2018-99-113399
Read the original:
New Approaches to the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma - Targeted Oncology
- New Atlas of Rare Stem and Progenitor Cells Reveals New Cell Types - Inside Precision Medicine - March 28th, 2024
- Instructing iPS cell-derived mesenchymal stem cells to inhibit abnormal bone formation in FOP - Medical Xpress - March 28th, 2024
- GLP podcast: GE crops have lived up to the hype; Growing 'mini' organs from stem cells; How do we solve right-wing ... - Genetic Literacy Project - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Stem cells: past, present, and future - PMC - National Center for ... - March 19th, 2024
- Stem cells: a comprehensive review of origins and emerging clinical ... - March 19th, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 19th, 2024
- What are Stem Cells? - Types, Applications and Sources - BYJU'S - March 19th, 2024
- Stem Cell - The Definitive Guide | Biology Dictionary - March 19th, 2024
- Colossal Creates Elephant Stem Cells for the First Time in Quest to Revive the Woolly Mammoth - Singularity Hub - March 19th, 2024
- Florida congresswoman sued the Pentagon over stem cells. One problem: her husband's stocks - Raw Story - January 23rd, 2024
- Can Stem Cells Improve Knee Pain or Are They A Waste of Money? - Bloomberg - January 23rd, 2024
- Stem cells used to successfully treat arthritis in gorilla at Budapest zoo - University of Sheffield News - January 23rd, 2024
- A computational model of stem cells' internal mechanism to recapitulate spatial patterning and maintain the self ... - Nature.com - January 23rd, 2024
- Advancing the generation of in-vivo chimeric lungs in mice using rat-derived stem cells - EurekAlert - January 6th, 2024
- 'I couldn't just give up on my dad' | Round Rock son donates stem cells to father battling leukemia - KVUE.com - January 6th, 2024
- Closing in on the ultimate quest to regenerate insulin in pancreatic stem cells - Medical Xpress - January 6th, 2024
- Ask the doctors: Research being conducted on using stem cells to treat diabetes - The Spokesman Review - January 6th, 2024
- Regenerative Medicine and COPD: Generating Functional Lungs from Pluripotent Stem Cells - Medriva - January 6th, 2024
- What is a stem cell? YourGenome - December 2nd, 2023
- Stem cell transplant - NHS - December 27th, 2022
- Stem cells: a brief history and outlook - Science in the News - December 27th, 2022
- RUDN Physician And Russian Scientists Investigate Long-term Effects Of Treating Diabetic Ulcers With Stem Cells - India Education Diary - December 27th, 2022
- Stem Cell Basics | STEM Cell Information - National Institutes of Health - December 2nd, 2022
- Neural stem cell - Wikipedia - November 24th, 2022
- Donate Stem Cells | Bone Marrow Donation - American Cancer Society - November 24th, 2022
- Stem Cells- Definition, Properties, Types, Uses, Challenges - November 6th, 2022
- Brothers from Karnataka, Prapul and Prajwal donated their stem cells, save two blood cancer patients - APN News - November 6th, 2022
- Getting These Stem Cells Treatments: Crippled Ronnie Coleman Gives a Positive Update on His Ability to Walk - EssentiallySports - October 21st, 2022
- Cornell Prof Explains Relevance of Creating Mouse Embryos from Stem Cells - Cornell University The Cornell Daily Sun - October 13th, 2022
- Human neuron clusters transplanted into rats offer new tool to study the brain : Shots - Health News - NPR - October 13th, 2022
- The neuroprotective effects of dental pulp stem cells and erythropoietin in mice hippocampus after ischemia-reperfusion - Newswise - October 13th, 2022
- A $7 million grant to grow stem cell research - Swinburne University of Technology - October 13th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Management, Personalized Medicine, and Genome... - October 13th, 2022
- Brennand named Elizabeth Mears and House Jameson Professor of Psychiatry - Yale News - October 13th, 2022
- American Academy of Stem Cell Physicians to Offer Licensed Physicians Board Examination in Regenerative Medicine - BioSpace - October 13th, 2022
- Stem Cells - alsa.org - October 4th, 2022
- Mouse embryo models built from stem cells take shape in a dish - Nature.com - October 4th, 2022
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 4th, 2022
- Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem... - October 4th, 2022
- Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from... - October 4th, 2022
- Research Shows Promise for Directing Later Lines of Therapy for Hodgkin Lymphoma - Targeted Oncology - October 4th, 2022
- Hereditary E200K mutation within the prion protein gene alters human iPSC derived cardiomyocyte function | Scientific Reports - Nature.com - September 25th, 2022
- How To Eat Your Way to Better Health According to a Doctor - Eat This, Not That - September 25th, 2022
- Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz... - September 25th, 2022
- Types of blood cancer: Leukemia, lymphoma, and more - Medical News Today - September 25th, 2022
- September: er-blood | News and features - University of Bristol - September 25th, 2022
- Here Is Why You Heal Slower As You Age - Health Digest - September 25th, 2022
- Global Single Cell Analysis Market is Projected to Grow at a CAGR of 15.1% By 2032: Visiongain Reports Ltd - Yahoo Finance UK - September 25th, 2022
- Findings explain exceptional auditory abilities in Williams-Beuren Syndrome - EurekAlert - September 25th, 2022
- Finding the potency in planarians | Communications Biology - Nature.com - September 16th, 2022
- Life-Saving Innovations in Cancer-Fighting Stem Cell Transplants and Pioneering Research in HIV, Autism and Cerebral Palsy to be Featured at World... - September 16th, 2022
- Treating Cancer with Oncolytic Viruses - BioPharm International - September 16th, 2022
- Israel's Profuse Technology Raises $2.5M for Technology That Lowers Cost of Cultured Meat - The Spoon - September 16th, 2022
- Stem Cells Used to Grow Mouse Embryo - BioTechniques - September 8th, 2022
- Largest Gift in UCSD History to Fund Stem Cell Research on Space Station - Times of San Diego - September 8th, 2022
- Global Induced Pluripotent Stem Cells Market (2022 to 2027) - Growth, Trends, Covid-19 Impact and Forecasts - ResearchAndMarkets.com - Business Wire - September 8th, 2022
- Health on the Frontlines: The Healing Power of Stem Cells - Dans Papers - September 8th, 2022
- Top 3 grants in regenerative medicine: July 2022 - RegMedNet - September 8th, 2022
- Childhood leukemia treatment 2022: Where we are now and what it takes - EurekAlert - September 8th, 2022
- Treatment Choices for AML Were Increasingly Influenced by Immunological Responses - Physician's Weekly - September 8th, 2022
- BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 - StreetInsider.com - September 8th, 2022
- Global Recombinant Cell Culture Supplements Market Report 2022: Increasing Need for Immunotherapies and Stem Cell and Regenerative Medicines Presents... - September 8th, 2022
- CAR-T Beyond CGTs In Development In 2022 - BioProcess Online - September 8th, 2022
- ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell Islets for the Treatment of Type 1 Diabetes - Business Wire - September 8th, 2022
- Synthetic Mouse Embryo with Brain and Beating Heart Grown from Stem Cells - Genetic Engineering & Biotechnology News - August 30th, 2022
- Utilization of Modified Induced Pluripotent Stem Cells as the Advance | OPTH - Dove Medical Press - August 30th, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - August 30th, 2022
- Brush Up: Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist - August 30th, 2022
- Regenerative Properties of the Newborn Heart Offers Hope for Those With Congenital Heart Disease - The Epoch Times - August 30th, 2022
- Kanpur hospital is Indias first to perform fat-derived stem cell transplant for diabetic patients - India Today - August 30th, 2022
- Scientists Just Genetically Edited a Million Years of Evolution Into Mouse DNA - ScienceAlert - August 30th, 2022
- Canadian Blood Services Stem Cells for Life - August 22nd, 2022
- Scientists say they have created 'embryos' without sperm or eggs - Medical News Today - August 22nd, 2022
- Many stem cell lines used for research and therapies carry large number of mutations, Cambridge researchers find - Cambridge Independent - August 22nd, 2022
- Scientists hope to revive extinct mammal through stem cells and gene-editing in a first - The Mirror - August 22nd, 2022
- Stem cell therapy in capsule form - Malaya - August 22nd, 2022
- Cell Culture Technician Pluripotent Stem Cell Biology and Genome Editing job with UNIVERSITY OF SOUTHAMPTON | 305107 - Times Higher Education - August 22nd, 2022
- Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs - The... - August 5th, 2022
- Self-organized anteroposterior regionalization of early midbrain and hindbrain using micropatterned human embryonic stem cells - Newswise - July 27th, 2022